{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-066946","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.261752+00:00","generated_at":"2026-05-22T03:48:50.258080+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Assembly Biosciences Q1 2025 net loss $8.8M; cash $91M; pipeline data expected in 2025","bullets":["Net loss $8.8M ($1.17/diluted share) vs $9.1M in Q1 2024; revenue from Gilead collaboration $9.4M (up from $5.8M).","Cash, equivalents and marketable securities $91.0M as of March 31, 2025; projected to fund operations into mid-2026.","R&D expenses $14.9M (up from $11.9M) driven by ABI-6250 and ABI-5366; G&A $4.5M (slight decrease from $4.6M).","Interim Phase 1b data for HSV candidates ABI-5366 and ABI-1179 expected in fall 2025; Phase 1a data for HDV candidate ABI-6250 in Q3 2025.","Phase 1b data for HBV candidate ABI-4334 (400 mg cohort) expected in H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-066946","json":"https://secwatch.observer/filing/0000950170-25-066946.json","markdown":"https://secwatch.observer/filing/0000950170-25-066946.md","text":"https://secwatch.observer/filing/0000950170-25-066946.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000095017025066946/0000950170-25-066946-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000095017025066946/asmb-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T03:48:50.258080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}